English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In a phase II study, responses and toxicity to single-agent gemcitabine chemotherapy were evaluated in patients with non-small-cell lung cancer (NSCLC) who had failed previous cisplatin-based chemotherapy.

Clinical Experience with Single-Agent Gemcitabine Chemotherapy in Patients with Non-Small-Cell Lung Cancer in Whom Previous Chemotherapy Has Failed